ברצוננו להודות לצוות של מתקן רכש רקמות של אוניברסיטת מינסוטה לקבלת סיוע באיסוף דגימות רקמת מטופל. עבודה זו נתמכה על ידי תכנית משרד ההגנה חקר סרטן השחלות (OCRP) OC093424 לMB, על ידי מחקר רנדי מכונת גילוח למלחמה בסרטן והקרן הקהילתית לMB, על ידי השחלות הברית למלחמה בסרטן מינסוטה לMB ועל ידי הקרן לגינקולוגיה אונקולוגיה המחלקתית לייט. היו הממנים שום תפקיד בעיצוב מחקר, איסוף נתונים וניתוח, החלטה לפרסם או הכנה של כתב היד.

הצהרת אתיקה דגימות מוצקות של סרטן השחלות התקבלו ממתקן אוניברסיטת מינסוטה רכש רקמות (TPF) לאחר מוסדי מועצה לביקורת הוועדה: אישור דירקטוריון הסובייקט אנושי (IRB). 1. התקנה מגיב <ol style=";text-align:right;direction:rtl"><li style=";text-align:right;direction:rtl"> להכין מדיום DMEM שלם על ידי השלמת DMEM עם 10% FBS, ו100 יחידות פניצילין, סטרפטומיצין. אחסן את המדיום על 4 מעלות צלזיוס וחמה 37 מעלות צלזיוס לפני שימוש. </li><li style=";text-align:right;direction:rtl"> dispase aliquot השני באמצעי אחסון נפרד של 5-10 מיליליטר, כדי למנוע הקפאה מרובה מפשיר ולאחסן ב -20 מעלות צלזיוס במקפיא ללא nonfrost. </li></ol> 2. אוסף רקמות <ol style=";text-align:right;direction:rtl"><li style=";text-align:right;direction:rtl"> לאסוף דגימות מוצקות של סרטן השחלות (~ 5 גרם בגודל) בזמן הניתוח מאזורי macroscopically זוהו כסרטן על ידי פתולוג. דגימות הקליניות מזוהה דה ונרשמו על פי פרוטוקולים מוסדיים. </li><li style=";text-align:right;direction:rtl"> הנח דגימות בסטרילי, scהמכסה REW, פוליפרופילן דגימות מיכל מלא ב30 מיליליטר של PBS קר כקרח. להעביר את הדגימות מהמעבדה לפתולוגיה כירורגית למעבדת המחקר לעיבוד על קרח, ובתוך 30 דקות מאיסוף דגימה (איור 1). </li></ol> 3. עיבוד רקמות <ol style=";text-align:right;direction:rtl"><li style=";text-align:right;direction:rtl"> עבודה בתנאים סטריליים, להעביר את הדגימות על צלחת פטרי (60 מ&quot;מ x 60 מ&quot;מ) המכיל 10 מיליליטר של PBS הטרי קר כקרח, ובאמצעות סכין סטרילי גילוח, לחתוך יותר לתוך החתיכות אפשריות (2 מ&quot;מ או פחות) הקטנות ביותר ( 2A דמויות ו2 ב &#39;). </li><li style=";text-align:right;direction:rtl"> העבר את הרקמות טחונות לתוך צינור חרוטי 15 מיליליטר מכיל 10 מיליליטר של prewarmed (37 מעלות צלזיוס במשך 30 דקות) dispase השני (2.4 U / ml) בDMEM ולדגור על 5% CO 2 ו37 מעלות צלזיוס במשך 30 דקות. כדי להבטיח עיכול מיטבי של הדגימות, להתסיס ידני תרחיף התא כל 5 דקות. </li><li style=";text-align:right;direction:rtl"> לאחר 30 דגירה דקות, העברה (באמצעותפיפטה סרולוגיות 10 מיליליטר) תרחיף התאים על גבי מסננת תא (70 רשת מיקרומטר) ממוקם על גבי צינור חרוטי 50 מיליליטר ולהחיל לחץ עדין נגד הרשת באמצעות בוכנת מזרק. לבטל את כל רקמת undissociated (שנותרה בחלק העליון של הרשת) ולאסוף את ההשעיה התא שהושגה בצינור חרוטי סטרילי 50 מיליליטר. צנטריפוגה ב320 XG במשך 7 דקות ב 4 ° C (איור 3). </li><li style=";text-align:right;direction:rtl"> בטל supernatant ו resuspend התא גלולה ב 10 מיליליטר של DMEM המכיל 10% FBS. </li><li style=";text-align:right;direction:rtl"> דגירה ההשעיה התא בצלחת פטרי ב 5% CO 2 ו37 ° C (איור 4). </li><li style=";text-align:right;direction:rtl"> שינוי הבינוני לאחר 24 שעות מהציפוי הראשוני. זה מאפשר להסרת פסולת הסלולר ורוב אריתרוציטים הווה בתרבות. </li><li style=";text-align:right;direction:rtl"> לשנות את המדיום כל שלושה ימים בשבועיים שלאחר מכן, לאחר שהתרבויות של EOC העיקרי מוכנות ליישומים במורד הזרם. </li></ol>

<ol>
	<li>Kurman, R. J., Visvanathan, K., Roden, R., Wu, T. C., Ie M, S. h. i. h. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early+detection+and+treatment+of+ovarian+cancer:+shifting+from+early+stage+to+minimal+volume+of+disease+based+on+a+new+model+of+carcinogenesis.">Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.</a> Am. J. Obstet. Gynecol. 198 (4), 351-356 (2008).</li><li>Kuhn, E., Kurman, R. J., Shih, I. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Ovarian+Cancer+Is+an+Imported+Disease:+Fact+or+Fiction.">Ovarian Cancer Is an Imported Disease: Fact or Fiction.</a> Curr. Obstet. Gynecol. Rep. 1 (1), 1-9 (2012).</li><li>Sarojini, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early+detection+biomarkers+for+ovarian.">Early detection biomarkers for ovarian.</a> J. Oncol. , (2012).</li><li>Shepherd, T. G., Theriault, B. L., Campbell, E. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Nachtigal+M.W.+Primary+culture+of+ovarian+surface+epithelial+cells+and+ascites-derived+ovarian+cancer+cells+from+patients.">Nachtigal M.W. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients.</a> Nat. Protoc. 1 (6), 2643-2649 (2006).</li><li>Tsao, S. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Characterization+of+human+ovarian+surface+epithelial+cells+immortalized+by+human+papilloma+viral+oncogenes+(HPV-E6E7+ORFs).">Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs).</a> Exp. Cell. Res. 218 (2), 499-507 (1995).</li><li>Auersperg, N., Maines-Bandiera, S. L., Dyck, H. G., Kruk, P. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Characterization+of+cultured+human+ovarian+surface+epithelial+cells:+phenotypic+plasticity+and+premalignant+changes.">Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes.</a> Lab. Invest. 71 (4), 510-518 (1994).</li><li>Brewer, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=In+vitro+model+of+normal,+immortalized+ovarian+surface+epithelial+and+ovarian+cancer+cells+for+chemoprevention+of+ovarian+cancer.">In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.</a> Gynecol. Oncol. 98 (2), 182-192 (2005).</li><li>Sueblinvong, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Establishment,+characterization+and+downstream+application+of+primary+ovarian+cancer+cells+derived+from+solid+tumors.">Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.</a> PLoS One. 7 (11), (2012).</li><li>Rockwell, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=In+vivo-in+vitro+tumour+cell+lines:+characteristics+and+limitations+as+models+for+human+cancer.">In vivo-in vitro tumour cell lines: characteristics and limitations as models for human cancer.</a> Br. J. Cancer Suppl. 41 (4), 118-122 (1980).</li><li>Wong, C., Chen, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+development,+application+and+limitations+of+breast+cancer+cell+lines+to+study+tamoxifen+and+aromatase+inhibitor+resistance.">The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.</a> J. Steroid. Biochem. Mol. Biol. 131 (3-5), 83-92 (2012).</li></ol>

יש המחברים אין לחשוף.

הבנה טובה יותר של האטיולוגיה סרטן השחלות ופיתוח היא חיונית לשיפור התוצאות של נשים מושפעות מהמחלה ההרסנית הזאת. בהקשר זה, השימוש בהוקם ו&quot; זמין מסחרי &quot;שורת תאי סרטן השחלות הייתה ללא ספק שימושית מאוד. עם זאת, היום אנחנו יודעים ששורות תאי הסרטן אינן נציג של הגידול הא?...

למרות השכיחות הנמוכה יחסית שלה, סרטן השחלות הוא הקטלני ביותר של מחלות גינקולוגיות והגורם המובילים החמישי של מקרי מוות מסרטן בקרב נשים 1,2. זאת, בעיקר בשל המחסור בכלים אמינים ומודלים שנאמנו לסכם ייזום והתקדמות המחלה 3. רוב הידע שלנו היום על סרטן השחלות היה אפשרי באמצעות השימוש בתאים הונצחו השחלות אפיתל פני השטח (IOSEs), שורות תאי סרטן השחלות וסרטן השחלות תאים ראשוניים התאוששו מ4-7 הנוזלים הרעיל. למרבה הצער, יש לו השימוש בם מספר מגבלות, כולל מספר השינויים הגנטיים ופנוטיפי הקשורים בתהליך הנצחה או במעברי מבחנה וההטרוגניות של האוכלוסייה כתוצאה מהכנת נוזלים רעילה. לכן, תאי סרטן השחלות עיקריים הנגזרים מדגימות מוצקות לזיהוי והספציפיים של סרטן השחלות מייצגים uniquכלי דואר לחקר התפתחות סרטן השחלות. הקשיים העיקריים המעורבים בתאים הממאירים אלה קבלת הם תוצאה של צמיחת יתר של תאי סטרומה או fibroblasts יחד עם הפסד של כדאיות וחוסר המוקדם של יכולת שגשוג בתרבות של תאי EOC אלה. כמה שיטות ליצירת תא בודד השעיות מגידולים מוצקים קיימות כיום, באמצעים מכאניים או ניתוק האנזימטית, לעומת זאת טכניקות מסוימות להניב כמות גדולה יותר של התוצאה המועדפת 8. כאן, אנו מראים כי עיכול אנזימטי עם dispase השני תוצאות בהתאוששות יעילה של תאי EOC קיימא, ללא פיברובלסטים. תרבויות EOC מה שהושגו הן רגישות מאוד למניפולציה גנטית ושימושיות גם בבדיקות סמים, מצביעים על כך שתרבויות EOC אלה מתאימות ליישומים רבים במורד הזרם.

<table border="0" cellpadding="0" cellspacing="0" width="720">
	<colgroup>
		<col />
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:275px;">Name of Material/ Equipment</td>
			<td style="width:125px;">Company</td>
			<td style="width:155px;">Catalog Number</td>
			<td style="width:167px;">Comments/Description</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">REAGENTS:</td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">1X PBS, sterile&#160;</td>
			<td style="width:125px;">Invitrogen</td>
			<td style="width:155px;">14190-144</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;">&#160;Screw lid, polypropylene specimen container, sterile (Thermoscientific)</td>
			<td style="width:125px;">Thermoscientific</td>
			<td style="width:155px;">02 1090</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">&#160;DMEM medium, sterile&#160;</td>
			<td style="width:125px;">Invitrogen</td>
			<td style="width:155px;">11995-065</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">&#160;Fetal bovine serum, sterile</td>
			<td style="width:125px;">Thermo Scientific Hyclone</td>
			<td style="width:155px;">SH30396.03</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;">&#160;100x penicillin-streptomycin, liquid (Invitrogen)</td>
			<td style="width:125px;">Invitrogen</td>
			<td style="width:155px;">15140-122</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">&#160;Dispase II, sterile (Roche)</td>
			<td style="width:125px;">Roche</td>
			<td style="width:155px;">04942 078 001</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">&#160;Small fine-tip forceps and scalpel blade, sterile</td>
			<td style="width:125px;">Fisher Scientific</td>
			<td style="width:155px;">forceps: 08-953E, blades: 08-927-5D</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">&#160;Small dissecting scissors, sterile</td>
			<td style="width:125px;">Fisher Scientific</td>
			<td style="width:155px;">08-945</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;">&#160;15 ml conical capped tubes, sterile (BD Falcon)</td>
			<td style="width:125px;">BD, Falcon</td>
			<td align="right" style="width:155px;">352097</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;">50 ml conical capped tubes, sterile (BD Falcon)</td>
			<td style="width:125px;">BD, Falcon</td>
			<td align="right" style="width:155px;">352027</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">&#160;10 ml serological pipette, sterile&#160;</td>
			<td style="width:125px;">Corning</td>
			<td style="width:155px;">13-678-11E</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">6 ml syringe plunger, sterile&#160;</td>
			<td style="width:125px;">Tyco Healthcare</td>
			<td align="right" style="width:155px;">8881516911</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;">Nylon filter (70 &#956;m ) cell strainer, sterile (BD Falcon)</td>
			<td style="width:125px;">BD Falcon</td>
			<td align="right" style="width:155px;">352350</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">5-cm Petri dish, sterile&#160;</td>
			<td style="width:125px;">Corning</td>
			<td align="right" style="width:155px;">430166</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;"></td>
			<td style="width:125px;"></td>
			<td style="width:155px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">10-cm Petri dish, sterile&#160;</td>
			<td style="width:125px;">Corning</td>
			<td align="right" style="width:155px;">430167</td>
			<td></td>
		</tr>
	</tbody>
</table>

method for obtaining primary ovarian cancer cells from solid specimens

כלים אמינים לחקירת ייזום סרטן השחלות ואת ההתקדמות נחוצים בדחיפות. בעוד שהשימוש בשורות תאי סרטן השחלות נשאר כלי רב ערך להבנת סרטן השחלות, יש השימוש בם מגבלות רבות. אלה כוללים את חוסר ההטרוגניות והשפע של שינויים גנטיים הקשורים passaging הממושך במבחנה. כאן אנו מתארים שיטה המאפשרת להקמה מהירה של תאי סרטן שחלות ראשוניים ליצור דגימות קליניות מוצקות שנאספו בזמן הניתוח. השיטה מורכבת מהכפפת דגימות קליניות לעיכול אנזימטי ל30 דקות. ההשעיה התא בודדת מותרת לגדול ויכולה לשמש ליישומים במורד הזרם, כולל הקרנת סמים. היתרון של שורות תאי סרטן השחלות עיקריות על שורות תאי סרטן השחלות הוקמו הוא שהם מייצגים את הדגימות הקליניות הספציפיות המקוריות הם נגזרים וניתן להפיק מן האתרים שונים אם פרימהסרטן השחלות ר&quot;י או גרורתי.

דגימות קליניות טריות של סרטן השחלות נאספות לאחר הניתוח (איור 1) וחותכים לחתיכות קטנות (2A דמויות ו2B) המהוות את תרחיף התא. זה מאפשר חשיפה אופטימלית של הדגימות לטיפול אנזימטי. תרחיף תא חשוף לעיכול אנזימטי וטופחו על C ° 37 ל30 דקות. במהלך זמן הדגירה slurry הופך ...

Watch this Scientific Journal Video about Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens at JoVE.com

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

מחקר זה מתאר שיטה מפורטת לבידוד ואפיון של תאי סרטן שחלות ראשוניים מדגימות קליניות מוצקות. דגימות קליניות בסרטן השחלות חשופים לעיכול אנזימטי לקבל סרטן קיימא, ללא פיברובלסטים אפיתל השחלות תאים (EOC) מתאים במיוחד עבור יישומים במורד הזרם.

שיטה לקבלת תאי סרטן השחלות ראשיים מתוך דגימות מוצקים

Reliable tools for investigating ovarian cancer initiation and progression are urgently needed. While the use of ovarian cancer cell lines remains a ...

method-for-obtaining-primary-ovarian-cancer-cells-from-solid-specimens

Research

JoVE Journal

Medicine

13.4K Views.  University of Minnesota.  מחקר זה מתאר שיטה מפורטת לבידוד ואפיון של תאי סרטן שחלות ראשוניים מדגימות קליניות מוצקות. דגימות קליניות בסרטן השחלות חשופים לעיכול אנזימטי לקבל סרטן קיימא, ללא פיברובלסטים אפיתל השחלות תאים (EOC) מתאים במיוחד עבור יישומים במורד הזרם. 

Video: Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

The current therapies for malignant glioma have only palliative effect. For therapeutic development, one hurdle is the discrepancy of efficacy determined by current drug efficacy tests and the efficacy on patients. Thus, novel and reliable methods for evaluating drug efficacy are warranted in pre-clinical phase. In vitro culture of tumor tissues, including cell lines, has substantial phenotypic, genetic, and epigenetic alterations of cancer cells caused by artificial environment of cell culture, which may not reflect the biology of original tumors in situ. Xenograft models with the immunodeficient mice also have limitations, i.e., the lack of immune system and interspecies genetic and epigenetic discrepancies in microenvironment. Here, we demonstrate a novel method using the surgical specimens of malignant glioma as undissociated tumor blocks to evaluate treatment effects. To validate this method, data with the current first-line chemotherapeutic agent, temozolomide (TMZ), are described.


We used the freshly-removed surgical specimen of malignant glioma for our experiments. We performed intratumoral injection of TMZ or other drug candidates, followed by incubation and analysis on surgical specimens. Here, we sought to establish a tumor tissue explant method as a platform to determine the efficacy of novel anti-cancer therapies so that we may be able to overcome, at least, some of the current limitations and fill the existing gap between the current experimental data and the efficacy on an actual patient's tumor. This method may have the potential to accelerate identifying novel chemotherapeutic agents for solid cancer treatment.

Here, we established a method for drug efficacy testing with surgical specimens of brain tumors, termed &#x201C;tumor explant method&#x201D;. With this method, we can evaluate drug efficacy without breaking the microenvironment of solid tumors. To validate reliability of this method, we describe representative data with our glioma specimen treated with the current first-line chemotherapeutic agent, temozolomide.

שיטה לפיתוח נגד סרטן רומן והתרופות באמצעות Explants גידול של דגימות כירורגי


The current therapies for malignant glioma have only palliative effect. For therapeutic development, one hurdle is the discrepancy of efficacy determined ...

Time-lapse Imaging of Primary Preneoplastic Mammary Epithelial Cells Derived from Genetically Engineered Mouse Models of Breast Cancer

Time-lapse imaging can be used to compare behavior of cultured primary preneoplastic mammary epithelial cells derived from different genetically engineered mouse models of breast cancer. For example, time between cell divisions (cell lifetimes), apoptotic cell numbers, evolution of morphological changes, and mechanism of colony formation can be quantified and compared in cells carrying specific genetic lesions. Primary mammary epithelial cell cultures are generated from mammary glands without palpable tumor. Glands are carefully resected with clear separation from adjacent muscle, lymph nodes are removed, and single-cell suspensions of enriched mammary epithelial cells are generated by mincing mammary tissue followed by enzymatic dissociation and filtration. Single-cell suspensions are plated and placed directly under a microscope within an incubator chamber for live-cell imaging. Sixteen 650 &mu;m x 700 &mu;m fields in a 4x4 configuration from each well of a 6-well plate are imaged every 15 min for 5 days. Time-lapse images are examined directly to measure cellular behaviors that can include mechanism and frequency of cell colony formation within the first 24 hr of plating the cells (aggregation versus cell proliferation), incidence of apoptosis, and phasing of morphological changes. Single-cell tracking is used to generate cell fate maps for measurement of individual cell lifetimes and investigation of cell division patterns. Quantitative data are statistically analyzed to assess for significant differences in behavior correlated with specific genetic lesions.

Time-lapse imaging is used to assess behavior of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer risk to determine if there are correlations between specific behavioral parameters and distinct genetic lesions.

הדמית זמן לשגות של תאי אפיתל חלב Preneoplastic ראשוניים הנגזרת ממודלי עכבר מהונדס גנטי של סרטן השד

Time-lapse  imaging can be used to compare behavior of cultured primary preneoplastic  mammary epithelial cells derived from different genetically ...

A Sensitive Method to Quantify Senescent Cancer Cells

Human cells do not indefinitely proliferate. Upon external and/or intrinsic cues, cells might die or enter a stable cell cycle arrest called senescence. Several cellular mechanisms, such as telomere shortening and abnormal expression of mitogenic oncogenes, have been shown to cause senescence. Senescence is not restricted to normal cells; cancer cells have also been reported to senesce.
	Chemotherapeutical drugs have been shown to induce senescence in cancer cells. However, it remains controversial whether senescence prevents or promotes tumorigenesis. As it might eventually be patient-specific, a rapid and sensitive method to assess senescence in cancer cell will soon be required.
	To this end, the standard &beta;-galactosidase assay, the currently used method, presents major drawbacks: it is time consuming and not sensitive. We propose here a flow cytometry-based assay to study senescence on live cells. This assay offers the advantage of being rapid, sensitive, and can be coupled to the immunolabeling of various cellular markers.

Whether senescence prevents or promotes tumorigenesis remains controversial. Since chemotherapeutical drugs can induce cancer cells to senesce, studying senescence is essential for proposing new therapies. However, the standard and broadly used &beta;-galactosidase assay presents major drawbacks. We propose here a rapid and sensitive flow cytometry-based assay to quantify senescence.

שיטה רגישה לכמת תאי סרטן senescent

Human cells do not indefinitely proliferate. Upon external and/or intrinsic  cues, cells might die or enter a stable cell cycle arrest called senescence. ...

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

The cancer stem cell (CSC) model has been considerably revisited over the last two decades. During this time CSCs have been identified and directly isolated from human tissues and serially propagated in immunodeficient mice, typically through antibody labeling of subpopulations of cells and fractionation by flow cytometry. However, the unique clinical features of prostate cancer have considerably limited the study of prostate CSCs from fresh human tumor samples. We recently reported the isolation of prostate CSCs directly from human tissues by virtue of their HLA class I (HLAI)-negative phenotype. Prostate cancer cells are harvested from surgical specimens and mechanically dissociated. A cell suspension is generated and labeled with fluorescently conjugated HLAI and stromal antibodies. Subpopulations of HLAI-negative cells are finally isolated using a flow cytometer. The principal limitation of this protocol is the frequently microscopic and multifocal nature of primary cancer in prostatectomy specimens. Nonetheless, isolated live prostate CSCs are suitable for molecular characterization and functional validation by transplantation in immunodeficient mice.

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.

בידוד של תאי גזע סרטני מדגימות אדם סרטן הערמונית

The cancer stem cell (CSC) model has been considerably revisited over the last two decades. During this time CSCs have been identified and directly ...

Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens

Many efforts have been devoted to establish in vitro cell culture systems. These systems are designed to model a vast number of in vivo processes. Cell culture systems arising from human endometrial samples are no exception. Applications range from normal cyclic physiological processes to endometrial pathologies such as gynecological cancers, infectious diseases, and reproductive deficiencies. Here, we provide two methods for establishing primary endometrial stromal cells from surgically resected endometrial hysterectomy specimens. The first method is referred to as &#8220;the scraping method&#8221; and incorporates mechanical scraping using surgical or razor blades whereas the second method is termed &#8220;the trypsin method.&#8221; This latter method uses the enzymatic activity of trypsin to promote the separation of cells and primary cell outgrowth. We illustrate step-by-step methodology through digital images and microscopy. We also provide examples for validating endometrial stromal cell lines via quantitative real time polymerase chain reactions (qPCR) and immunofluorescence (IF).

Establishing primary endometrial stromal cell culture systems from hysterectomy specimens is a valuable biological technique and a crucial step prior to pursuing a vast array of research aims. Here, we describe two methods used to establish stromal cultures from surgically resected endometrial tissues of human patients.&#160;

שתי שיטות לקביעת אדם תאי רירית הרחם סטרומה ראשיים מדוגמאות כריתת הרחם

Many efforts have been devoted to establish in vitro cell culture systems. These systems are designed to model a vast number of in vivo processes. Cell ...

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Ovarian cancers metastasize by shedding into the peritoneal fluid and dispersing to distal sites within the peritoneum. Monolayer cultures do not accurately model the behaviors of cancer cells within a nonadherent environment, as cancer cells inherently aggregate into multicellular structures which contribute to the metastatic process by attaching to and invading the peritoneal lining to form secondary tumors. To model this important stage of ovarian cancer metastasis, multicellular aggregates, or spheroids, can be generated from established ovarian cancer cell lines maintained under nonadherent conditions. To mimic the peritoneal microenvironment encountered by tumor cells in vivo, a spheroid-mesothelial co-culture model was established in which preformed spheroids are plated on top of a human mesothelial cell monolayer, formed over an extracellular matrix barrier. Methods were then developed using a real-time cell analyzer to conduct quantitative real time measurements of the invasive capacity of different ovarian cancer cell lines grown as spheroids. This approach allows for the continuous measurement of invasion over long periods of time, which has several advantages over traditional endpoint assays and more laborious real time microscopy image analyses. In short, this method enables a rapid, determination of factors which regulate the interactions between ovarian cancer spheroid cells invading through mesothelial and matrix barriers over time.

Ovarian cancer cell invasion into the mesothelial lining of the peritoneum is a dynamic process over time. Utilizing a real time analyzer, the invasive capacity of ovarian cancer cells in a spheroid-mesothelial cell co-culture model can be quantified over prolonged time periods, providing insights into factors regulating the metastatic process.

הערכה של קובץ מצורף סרטן השחלות אליפטית ופלישה של תאי mesothelial בזמן אמת

Ovarian cancers metastasize by shedding into the peritoneal fluid and dispersing to distal sites within the peritoneum. Monolayer cultures do not ...

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States. Although patients initially respond to the current standard of care consisting of surgical debulking and combination chemotherapy consisting of platinum and taxane compounds, almost 90% of patients recur within a few years. In these patients the development of chemoresistant disease limits the efficacy of currently available chemotherapy agents and therefore contributes to the high mortality. To discover novel therapy options that can target recurrent disease, appropriate animal models that closely mimic the clinical profile of patients with recurrent ovarian cancer are required. The challenge in monitoring intra-peritoneal (i.p.) disease limits the use of i.p. models and thus most xenografts are established subcutaneously. We have developed a sensitive optical imaging platform that allows the detection and anatomical location of i.p. tumor mass. The platform includes the use of optical reporters that extend from the visible light range to near infrared, which in combination with 2-dimensional X-ray co-registration can provide anatomical location of molecular signals. Detection is significantly improved by the use of a rotation system that drives the animal to multiple angular positions for 360 degree imaging, allowing the identification of tumors that are not visible in single orientation. This platform provides a unique model to non-invasively monitor tumor growth and evaluate the efficacy of new therapies for the prevention or treatment of recurrent ovarian cancer.

We describe a non-invasive animal imaging platform that allows the detection, quantification, and monitoring of ovarian cancer growth and recurrence. This intra-peritoneal xenograft model mimics the clinical profile of patients with ovarian cancer.

דגם Murine הדמיה בלתי פולשנית לזיהוי ומעקב סרטן השחלות הישנות

Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States. Although patients initially respond to the current standard of ...

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Cancer stem cells (CSCs) are defined as a subset of slow cycling and undifferentiated cells that divide asymmetrically to generate highly proliferative, invasive, and chemoresistant tumor cells. Therefore, CSCs are an attractive population of cells to target therapeutically. CSCs are predicted to contribute to a number of types of malignancies including those in the blood, brain, lung, gastrointestinal tract, prostate, and ovary. Isolating and enriching a tumor cell population for CSCs will enable researchers to study the properties, genetics, and therapeutic response of CSCs. We generated a protocol that reproducibly enriches for ovarian cancer CSCs from ovarian cancer cell lines (SKOV3 and OVCA429). Cell lines are treated with 20 &#181;M cisplatin for 3 days. Surviving cells are isolated and cultured in a serum-free stem cell media containing cytokines and growth factors. We demonstrate an enrichment of these purified CSCs by analyzing the isolated cells for known stem cell markers Oct4, Nanog, and Prom1 (CD133) and cell surface expression of CD177 and CD133. The CSCs exhibit increased chemoresistance. This method for isolation of CSCs is a useful tool for studying the role of CSCs in chemoresistance and tumor relapse.

Cancer stem cells (CSCs) are&#160;implicated in tumor relapse due to chemoresistance. We have optimized a protocol for selection and expansion of CSCs from ovarian cancer cell lines. By treating cells with the chemotherapeutic cisplatin and culturing&#160;in a stem cell promoting media we enrich for non-adherent CSC cultures.

העשרה לתאי גזע Chemoresistant סרטן השחלות משורות תאים אנושיות

Cancer stem cells (CSCs) are defined as a subset of slow cycling and undifferentiated cells that divide asymmetrically to generate highly proliferative, ...

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

In-depth analyses of cancer cell proteomes are needed to elucidate oncogenic pathomechanisms, as well as to identify potential drug targets and diagnostic biomarkers. However, methods for quantitative proteomic characterization of patient-derived tumors and in particular their cellular subpopulations are largely lacking. Here we describe an experimental set-up that allows quantitative analysis of proteomes of cancer cell subpopulations derived from either liquid or solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry followed by bioinformatic data analysis. To enrich specific cellular subsets, liquid tumors are first immunophenotyped by flow cytometry followed by FACS-sorting; for solid tumors, laser-capture microdissection is used to purify specific cellular subpopulations. In a second step, proteins are extracted from the purified cells and subsequently combined with a tumor-specific, SILAC-labeled spike-in standard that enables protein quantification. The resulting protein mixture is subjected to either gel electrophoresis or Filter Aided Sample Preparation (FASP) followed by tryptic digestion. Finally, tryptic peptides are analyzed using a hybrid quadrupole-orbitrap mass spectrometer, and the data obtained are processed with bioinformatic software suites including MaxQuant. By means of the workflow presented here, up to 8,000 proteins can be identified and quantified in patient-derived samples, and the resulting protein expression profiles can be compared among patients to identify diagnostic proteomic signatures or potential drug targets.

In-depth analyses of cancer cell proteomes facilitate identification of novel drug targets and diagnostic biomarkers. We describe an experimental workflow for quantitative analysis of (phospho-)proteomes in cancer cell subpopulations derived from liquid and solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry.

Mass כמותי spectrometric פרופיל של Proteomes סרטן התאים נגזרים מנוזלים וגידולים מוצקים

In-depth analyses of cancer cell proteomes are needed to elucidate oncogenic pathomechanisms, as well as to identify potential drug targets and diagnostic ...

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Evidence suggests that small subpopulations of tumor cells maintain a unique self-renewing and differentiation capacity and may be responsible for tumor initiation and/or relapse. Clarifying the mechanisms by which these tumor-initiating cells (TICs) support tumor formation and progression could lead to the development of clinically favorable therapies. Ovarian cancer is a heterogeneous and highly recurrent disease. Recent studies suggest TICs may play an important role in disease biology. We have identified culture conditions that enrich for TICs from ovarian cancer cell lines. Growing either adherent cells or non-adherent &#8216;floater&#8217; cells in a low attachment plate with serum free media in the presence of growth factors supports the propagation of ovarian cancer TICs with stem cell markers (CD133 and ALDH activity) and increased tumorigenicity without the need to physically separate the TICs from other cell types within the culture. Although the presence of floater cells is not common for all cell lines, this population of cells with innate low adherence may have high tumorigenic potential.Compared to adherent cells grown in the presence of serum, TICs readily form spheres, are significantly more tumorigenic in mice, and express putative stem cell markers. The conditions are easy to establish in a timely manner and can be used to study signaling pathways important for maintaining stem characteristics, and to identify drugs or combinations of drugs targeting TICs. The culture conditions described herein are applicable for a variety of ovarian cancer cells of epithelial origin and will be critical in providing new information about the role of TICs in tumor initiation, progression, and relapse.

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Tumor-initiating cells (TICs) may represent a viable therapeutic target for the treatment of ovarian cancer, a highly recurrent and fatal disease. We present a protocol for culture conditions that enrich for this highly tumorigenic population of cells.

בהעשרת מבחנה של תאי ייזום-גידול סרטן השחלות

Evidence suggests that small subpopulations of tumor cells maintain a unique self-renewing and differentiation capacity and may be responsible for tumor ...